Extracorporeal photochemotherapy (ECP) was developed at Columbia Presbyterian Medical Center in the early 1980s for the treatment of cutaneous T-cell lymphoma (CTCL). ECP is now used primarily in the treatment of that disease at more than 100 centers worldwide. It also has been shown to be potentially effective in treating several autoimmune diseases. Most recently, it has been used in reversing solid-organ transplant rejection and graft-versus-host disease following bone-marrow transplantation. In this article, we present the case of one of the first patients treated with ECP and give an update on the current status of this therapy.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Combination treatment of extracorporeal photopheresis and belumosudil for chronic graft-versus-host disease.
Arch Dermatol Res
January 2025
Department of Dermatology, Yale School of Medicine, New Haven, CT, USA.
Extracorporeal Photopheresis, a Therapeutic Alternative for T cell-mediated Rejection in Renal Transplantation.
Transplant Proc
January 2025
Nefrology Department, Universitary Hospital Virgen de la Arrixaca, Murcia, Spain.
T-cell mediated rejection (TCMR) in renal transplantation, although reduced by better immunosuppressants, still impacts graft survival. TCMR responds to methylprednisolone (MPL) in 60% to 70% of cases, with polyclonal anti-T-lymphocyte antibodies (ATGs) used for severe or corticoresistant cases. When ATG is contraindicated, extracorporeal photopheresis (ECP) may be an alternative.
View Article and Find Full Text PDFA paired study comparing mononuclear cell collection using a new in-line system with an off-line extracorporeal photopheresis apheresis system.
Transfusion
January 2025
Hematology Department, Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, Madrid, Spain.
Background: Extracorporeal photopheresis (ECP) product characteristics are not well established. The aim of this study was to compare mononuclear cells (MNCs) collection using the new Amicus blue (AB) In-line ECP system to our standard Off-line ECP system using the Optia apheresis device and the MacoGenic G2 inactivation system (OM).
Study Design And Methods: We assessed the ECP products and procedure parameters, patient characteristics, and adverse events for both AB and OM systems in paired patients.
Antitumor immunostimulatory effect via cell-killing action of a novel extracorporeal blood circulating photodynamic therapy system using 5-aminolevulinic acid.
Sci Rep
January 2025
Research Division, JIMRO Co., Ltd., Takasaki, Japan.
This study investigated whether intravenous administration of tumor cells killed by photodynamic therapy (PDT) with 5-aminolevulinic acid (5-ALA) had antitumor effects on distal tumors. Furthermore, a novel extracorporeal blood circulating 5-ALA/PDT system was developed. 5-ALA/PDT- (low or high irradiation) or anticancer drug-treated cells were intravenously administered to rats in a glioma cancer model.
View Article and Find Full Text PDFThere are no good evidence-based recommendations for any systemic treatment of erosive lichen planus (ELP). Extracorporeal photopheresis (ECP) may be an effective therapy for recalcitrant forms of the disease. We report 3 patients with severe ELP treated with ECP.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!